Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The U.S. Food and Drug Administration approved the first and only antipsychotic for the acute treatment of schizoaffective disorder. INVEGA extended–release tablets were approved for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. INVEGA was approved in 2006 for the treatment of schizophrenia. Janssen, Division of Ortho–McNeil–Janssen Pharmaceuticals, Inc, markets INVEGA in the U.S.


Today in Drug Approvals...keeping you current

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/22/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

Today in Drug/Product Alerts...keeping you current

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

Generic Anticonvulsant Use in Children: Do We Have Evidence to Recommend Brand Formulations?
Archives of Neurology, 11/23/09

FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 11/02/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address